Adding additional strengths to the company's executive team, Mr. Oxley brings extensive experience in developing corporate strategy, leading cross-borders licensing transactions, and global capital markets strategy to the company. With a unique combination of experience in next-generation genetic and cellular medicine, Mr. Oxley's credentials include designing and prosecuting the construction of a complex cellular medicine business plan for Hong Kong Listing in China and the Asia Pacific, commercializing first-in-category products, and leading global cross-border licensing transactions. In addition, Mr. Oxley brings experience building high-performing global sales and marketing organizations to support the company's strategic plan.

BIORCHESTRA's Scientific Founder, Chairman, and Chief Executive Officer, Dr. Branden Ryu, commented: "We are delighted to add Mr. Oxley to our executive leadership team. Mr. Oxley brings unique global commercial and investment banking skillsets to enhance our executive management functions.  As we accelerate the development of our lead program, BMD-001, within our neurological diseases franchise targeting Alzheimer's disease (AD), Amyotrophic Lateral Sclerosis (ALS), and Parkinson's disease (PD), Mr. Oxley will play a critical commercial strategy, licensing, and capital markets leadership role within our global organization."

"In addition to his expertise in the U.S. capital markets and overseeing global, cross-border commercialization and licensing functions, Mr. Oxley's expansive knowledge and experience in China and throughout Asia will bring added value to our global strategy," said Dr. Louis St. L. O'Dea, President & Chief Medical Officer.  "As part of our global strategic plan, we are assembling an executive team that leverages the world-class RNA, genetic-medicine research, pharmacological, commercial, and investment banking resources around the Boston/Cambridge hub," added Dr. O'Dea. "This team now includes Mr. Oxley's extensive corporate strategy and global commercial and capital markets experience, and we look forward to his contributions," Dr. O'Dea concluded.   

"Mr. Oxley will serve a vital role in prosecuting our global corporate strategy," said Mr. Young-Gil Kim, Chief Financial Officer.  "Mr. Oxley joins the company ahead of significant stages of strategic growth where his capital markets contributions to our financial strategy and plan execution will be essential," Mr. Kim concluded. 

"World-class researchers at BIORCHESTRA, led by Dr. Ryu, have discovered a rare epigenetic target common across Alzheimer's disease, Amyotrophic Lateral Sclerosis, and Parkinson's disease and successfully developed a proprietary, IV-formulated RNA encapsulation approach, with very encouraging in-vivo results across rodent, and non-human primate models," said Mr. Oxley.  Commenting on the transformational IV approach to unlocking the broad therapeutic application of nucleic-acid-based medicines targeting degenerative diseases of the Central Nervous System, Mr. Oxley said, "Significant downregulation of the epigenetic target across diverse brain regions following IV injection at a non-toxic, low dose is a highly encouraging outcome. The promise inherent in BMD-001 to offer a potential first and best-in-class RNAi therapeutic to patients with certain neurodegenerative diseases is inspiring," Mr. Oxley added.  "It is a privilege to join this extraordinary team of passionate researchers unified by a common mission," Mr. Oxley concluded